Evidence current through August 2026

Tesamorelin

Tesamorelin is a synthetic analogue of the human growth hormone–releasing hormone sequence GHRH(1–44). A trans-3-hexenoic-acid modification at the N-terminus increases resistance to enzymatic degradation while preserving activity at the GHRH receptor.

That receptor-level design distinguishes tesamorelin from compounds that act directly at the growth hormone receptor. In the investigated clinical products, GHRH-receptor activation stimulated pituitary growth hormone release and increased downstream insulin-like growth factor 1 (IGF-1). The pathway retains more of the pituitary axis than direct administration of growth hormone, although increased GH–IGF-1 signaling remains central to both the observed endpoints and the safety questions.

Research areas

HIV-associated VAT
Continued treatment
Withdrawal
Body weight
Liver fat
Cognition
Muscle and function
Safety

Evidence at a glance

What the current record supports

HIV-associated VAT: Two replicated Phase 3 randomized trials reported significant reductions in CT-measured VAT at 26 weeks

Continued treatment: Extension data reported maintenance or additional VAT change through 52 weeks among continuing participants

Withdrawal: Randomized withdrawal data reported reaccumulation after the investigated treatment stopped

Body weight: Pivotal trials did not establish tesamorelin as a general weight-loss intervention

Qualification

Limitations and evidence gaps

Limitations and contradictory findings

The strongest evidence is specific to adults with HIV-associated lipodystrophy and a reduction in CT-measured visceral adipose tissue. It should not be generalized to broad weight loss or treated as proof of fewer cardiovascular events, diabetes complications, hospitalizations, or deaths. Many later findings are secondary or post-hoc analyses of the same phase III cohorts, while liver, cognition, and physical-function questions rely on small samples, indirect evidence, or studies without complete published results.

Controlled evidence is concentrated at 26 weeks, with selected extension data to 52 weeks. Durability after withdrawal, multi-year outcomes, independent replication, and applicability to contemporary obesity or understudied populations remain unresolved.

Safety and evidence gaps

Trials identify injection-site reactions, hypersensitivity, fluid-retention effects, glucose intolerance in a susceptible minority, and frequent IGF-1 elevation. The available duration cannot resolve long-latency malignancy, major cardiovascular events, retinopathy, severe hyperglycemia, or uncommon immune effects.

Evidence is insufficient in pediatric and older populations and in people with renal or hepatic impairment, poorly controlled diabetes, recent malignancy, or disrupted pituitary function. Known biological concerns should be treated as uncertainty rather than proof that long-term harm is either present or absent.

Research path

Connected research articles

Overview

Tesamorelin Research Overview

Read overview

Full review

Tesamorelin: Full Evidence Review

Looking for the shorter version? Start with the Tesamorelin Research Overview, written for readers who want the main findings without the full technical detail.

Read evidence review

Study map

Connected study records

Published protocol and registry-only recordsSee approved evidence mapOngoing

BMJ Open

TES-STUDY-P001

Erlandson KM, et al. Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol. BMJ Open. 2026;16:e120740. DOI: 10.1136/bmjopen-2026-120740. PMID: 42419889. NCT06554717. https://bmjopen.bmj

View study